title: UK guidance opens new therapeutic avenues for patients with moderate-severe ulcerative colitis.
authors.affiliation: a GI Unit , St Mary's Hospital, Imperial College Healthcare NHS Trust, Imperial College London , London , UK.
authors.forename: Tim
authors.initials: T
authors.lastname: Orchard
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors / Q000276:immunology; D058990:Molecular Targeted Therapy; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology; D006113:United Kingdom
chemical_list: D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D016023:Integrins; D014409:Tumor Necrosis Factor-alpha